These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 32154610

  • 1. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, Glerum PJ, Herberts C, Babae N, Herold R, Papadouli I, Pignatti F.
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [Abstract] [Full Text] [Related]

  • 2. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N.
    Cochrane Database Syst Rev; 2015 Oct 20; 2015(10):CD010615. PubMed ID: 26484982
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
    Ji MM, Shen YG, Gong JC, Tang W, Xu XQ, Zheng Z, Chen SY, He Y, Zheng X, Zhao LD, Zhao WL, Wu W.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb 14; 44(2):112-117. PubMed ID: 36948864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost.
    Sohutskay DO, Tetrick AM, Goebel WS, Schwering D, Reddy MS.
    J Clin Apher; 2024 Oct 14; 39(5):e22145. PubMed ID: 39291715
    [Abstract] [Full Text] [Related]

  • 10. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M, Silva M.
    Clin Ther; 2010 May 14; 32(5):821-43. PubMed ID: 20685493
    [Abstract] [Full Text] [Related]

  • 11. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
    Transfusion; 2011 May 14; 51(5):968-75. PubMed ID: 20880037
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M.
    Haematologica; 2024 May 01; 109(5):1525-1534. PubMed ID: 37981892
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
    Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT, Partisano AM, Marulkar S, DiPersio JF.
    Am J Hematol; 2013 Dec 01; 88(12):1017-23. PubMed ID: 23907769
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis.
    Li Y, Qiu X, Lei Y, Zhou R.
    Ann Med; 2024 Dec 01; 56(1):2329140. PubMed ID: 38470973
    [Abstract] [Full Text] [Related]

  • 17. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
    Nahi H, Celanovic M, Liu Q, Lund J, Peceliunas V.
    Biol Blood Marrow Transplant; 2019 Jan 01; 25(1):34-40. PubMed ID: 30149148
    [Abstract] [Full Text] [Related]

  • 18. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J, Dipersio JF, Bolwell BJ.
    Biol Blood Marrow Transplant; 2013 Apr 01; 19(4):670-5. PubMed ID: 23333777
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
    DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators.
    J Clin Oncol; 2009 Oct 01; 27(28):4767-73. PubMed ID: 19720922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.